Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-009929
Filing Date
2024-03-14
Accepted
2024-03-14 14:06:34
Documents
72
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1014309
2 ex31-1.htm EX-31.1 8586
3 ex31-2.htm EX-31.2 8755
4 ex32-1.htm EX-32.1 4076
5 ex32-2.htm EX-32.2 4347
  Complete submission text file 0001493152-24-009929.txt   5999037

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE vtro-20240131.xsd EX-101.SCH 54283
7 XBRL CALCULATION FILE vtro-20240131_cal.xml EX-101.CAL 71082
8 XBRL DEFINITION FILE vtro-20240131_def.xml EX-101.DEF 204989
9 XBRL LABEL FILE vtro-20240131_lab.xml EX-101.LAB 427539
10 XBRL PRESENTATION FILE vtro-20240131_pre.xml EX-101.PRE 315408
73 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 919424
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

EIN.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41766 | Film No.: 24749082
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)